Weekly Research Analysts’ Ratings Updates for REGENXBIO (RGNX)

REGENXBIO (NASDAQ: RGNX) recently received a number of ratings updates from brokerages and research firms:

• 11/24/2025 – REGENXBIO was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/20/2025 – REGENXBIO had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.
• 11/16/2025 – REGENXBIO was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 11/8/2025 – REGENXBIO was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/7/2025 – REGENXBIO had its price target raised by analysts at Royal Bank Of Canada from $17.00 to $19.00. They now have an “outperform” rating on the stock.
• 10/8/2025 – REGENXBIO had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/7/2025 – REGENXBIO had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $34.00 price target on the stock.

Insider Buying and Selling at REGENXBIO

In related news, CEO Curran Simpson sold 20,811 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $12.62, for a total transaction of $262,634.82. Following the sale, the chief executive officer directly owned 216,162 shares in the company, valued at $2,727,964.44. This trade represents a 8.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 36,169 shares of company stock valued at $416,598 in the last ninety days. 12.79% of the stock is owned by corporate insiders.

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.